AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
AAPL   321.44 (+1.05%)
MSFT   182.42 (+0.33%)
FB   229.57 (+0.19%)
GOOGL   1,432.17 (+0.84%)
AMZN   2,422.84 (+0.52%)
NVDA   347.14 (+1.80%)
BABA   200.25 (-0.46%)
GE   7.08 (-2.88%)
TSLA   818.12 (-0.26%)
AMD   53.36 (+1.18%)
T   31.51 (-1.10%)
ACB   16.37 (+6.99%)
DIS   118.72 (-2.31%)
NFLX   421.09 (+0.29%)
BAC   25.23 (-2.89%)
BA   154.53 (+3.35%)
Log in

NASDAQ:HSGXHistogenics Stock Price, Forecast & News

$0.32
-0.01 (-3.00 %)
(As of 05/28/2020 12:35 PM ET)
Add
Compare
Today's Range
$0.31
Now: $0.32
$0.34
50-Day Range
$0.26
MA: $0.33
$0.47
52-Week Range
$0.08
Now: $0.32
$1.43
Volume10.96 million shs
Average Volume10.71 million shs
Market Capitalization$30.56 million
P/E RatioN/A
Dividend YieldN/A
Beta3.1
Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Read More
Histogenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.76 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.01) per share

Profitability

Net Income$-8,640,000.00

Miscellaneous

Employees49
Market Cap$30.56 million
Next Earnings Date8/7/2020 (Estimated)
OptionableNot Optionable

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

How has Histogenics' stock been impacted by COVID-19 (Coronavirus)?

Histogenics' stock was trading at $0.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSGX shares have decreased by 19.3% and is now trading at $0.3230. View which stocks have been most impacted by Coronavirus.

When is Histogenics' next earnings date?

Histogenics is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Histogenics.

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) released its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.10. View Histogenics' earnings history.

Has Histogenics been receiving favorable news coverage?

News stories about HSGX stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Histogenics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutHistogenics.

Who are some of Histogenics' key competitors?

What other stocks do shareholders of Histogenics own?

Who are Histogenics' key executives?

Histogenics' management team includes the following people:
  • Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)
  • Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
  • Mr. Stephen R. Kennedy, Consultant (Age 62)

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $0.32.

How big of a company is Histogenics?

Histogenics has a market capitalization of $30.56 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe.

What is Histogenics' official website?

The official website for Histogenics is www.histogenics.com.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.